Publications

  1. Choo R, Hillman DW, Mitchell C, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky TM, Davis BJ, Amundson A, Wong W. Five-Year Outcomes of Moderately Hypofractionated Proton Therapy Incorporating Elective Pelvic Nodal Irradiation for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025 May 1; 122 (1):99-108 Epub 2024 Dec 11
    View PubMed
  2. Gergelis KR, Bai M, Ma J, Routman DM, Stish BJ, Davis BJ, Pisansky TM, Whitaker TJ, Choo R. Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer. Curr Oncol. 2025 Apr 2; 32 (4) Epub 2025 Apr 02
    View PubMed
  3. Wisdom AJ, Yeap BY, Michalski JM, Horick NK, Zietman AL, Christodouleas JP, Kamran SC, Parikh RR, Vapiwala N, Mihalcik S, Miyamoto DT, Zeng J, Gay HA, Pisansky TM, Mishra MV, Spratt DE, Mendenhall NP, Soffen EM, Bekelman JE, Efstathiou JA. Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025 Mar 1; 121 (3):741-751 Epub 2024 Sept 30
    View PubMed
  4. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 2024 Jul 10; 42 (20):2377-2381 Epub 2024 May 17
    View PubMed
  5. Gao RW, Ma J, Pisansky TM, Kruse JJ, Stish BJ, Kowalchuk RO, McMenomy BP, Waddle MR, Phillips RM, Choo R, Davis BJ. Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer. Int J Part Ther. 2024 Jun; 12:100015 Epub 2024 Apr 24
    View PubMed
  6. Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. 2024 Apr; 85 (4):373-381 Epub 2023 Jan 28
    View PubMed
  7. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10 (2):271-278 Epub 2024 Feb 01
    View PubMed
  8. Lee WR, Dignam JJ, Amin M, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes I, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers J, Sandler HM. Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Oct 1; 117 (2S):S3-S4
    View PubMed
  9. Lee JY, Dess RT, Zelefsky MJ, Davis BJ, Horwitz EM, Cooperberg MR, Zaorsky NG, Jia AY, Sandler HM, Efstathiou JA, Pisansky TM, Hall E, Tree A, Roy S, Bolla M, Nabid A, Zapatero A, Kishan AU, Spratt DE, Sun Y. Individual Patient Data Analysis of 17 Randomized Trials vs. Real-World Data for Men with Localized Prostate Cancer Receiving Radiotherapy. Int J Radiat Oncol Biol Phys. 2023 Oct 1; 117 (2S):e404-e405
    View PubMed
  10. Wisdom AJ, Yeap BY, Michalski JM, Zietman AL, Baumann BC, Christodouleas JP, Kamran SC, Parikh RR, Vapiwala N, Ellis RJ 3rd, Hartsell WF, Miyamoto DT, Zeng J, Pisansky TM, Mishra MV, Spratt DE, Mendenhall NP, Soffen EM, Bekelman JE, Efstathiou JA. Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Oct 1; 117 (2S):e450
    View PubMed
  11. Bai J, Pugh SL, Eldridge R, Yeager KA, Zhang Q, Lee WR, Shah AB, Dayes IS, D'Souza DP, Michalski JM, Efstathiou JA, Longo JM, Pisansky TM, Maier JM, Faria SL, Desai AB, Seaward SA, Sandler HM, Cooley ME, Bruner DW. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. Int J Radiat Oncol Biol Phys. 2023 May 1; 116 (1):39-49 Epub 2023 Feb 02
    View PubMed
  12. Choo R, Hillman DW, Mitchell C, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis BJ, Amundson A, Wong W. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 115 (5):1085-1094 Epub 2022 Nov 22
    View PubMed
  13. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023 Mar 1; 115 (3):645-653 Epub 2022 Sept 28
    View PubMed
  14. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O, NRG Prostate Cancer AI Consortium. Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2023 Feb 22; 6 (1):27
    View PubMed
  15. Ma TM, Sun Y, Malone S, Roach M 3rd, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 Feb 1; 41 (4):881-892 Epub 2022 Oct 21
    View PubMed
  16. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M 3rd, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU, Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). Eur Urol. 2022 Nov; 82 (5):487-498 Epub 2022 Aug 05
    View PubMed
  17. Wong WW, Hillman DW, Daniels TB, Vargas CE, Rwigema JC, Corbin KS, Keole SR, Merrell KW, Stish BJ, Pisansky TM, Davis BJ, Mitchell CM, Choo R. A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life. Prostate. 2022 Oct; 82 (14):1338-1345 Epub 2022 July 05
    View PubMed
  18. Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, Spratt DE. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. J Clin Oncol. 2022 Sep 20; 40 (27):3172-3179 Epub 2022 June 23
    View PubMed
  19. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O, NRG Prostate Cancer AI Consortium. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022 Jun 8; 5 (1):71 Epub 2022 June 08
    View PubMed
  20. Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng F, Mishra MV. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform. 2022 Jun; 6:e2100188
    View PubMed
  21. Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M 3rd, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). Int J Radiat Oncol Biol Phys. 2022 Apr 1; 112 (5):1115-1122 Epub 2021 Nov 03
    View PubMed
  22. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer a patient-level data analysis of 3 cohorts. JAMA Oncology. 2022 Mar; 8 (3):e216871
  23. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 1; 8 (3):e216871 Epub 2022 Mar 17
    View PubMed
  24. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE, MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb; 23 (2):304-316 Epub 2022 Jan 17
    View PubMed
  25. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M 3rd, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, Spratt DE, Kishan AU. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 Dec 1; 4 (12):e2139769 Epub 2021 Dec 01
    View PubMed
  26. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 Dec 1; 4 (12):e2138550 Epub 2021 Dec 01
    View PubMed
  27. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  28. Kishan AU, Sun Y, Pisansky TM, Bolla M, Steigler A, Denham JW, Shipley WU, Sandler HM, Feng FY, Joseph DJ, Armstrong JG, Dunne M, Zapatero A, Ma TM, Romero T, Wang X, Steinberg ML, Jackson WC, Dess RT, Spratt DE. Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S5-S6
    View PubMed
  29. Dess RT, Sun Y, Bolla M, Zapatero A, Malone S, Kishan AU, Roy S, Jackson WC, Lawton CAF, Sartor O, Nguyen PL, Michalski JM, Pisansky TM, Roach M 3rd, Sandler HM, Schipper M, Feng FY, Spratt DE. Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S78
    View PubMed
  30. Kishan AU, Romero T, Wang X, Pisansky TM, Roach M 3rd, Bolla M, Steigler A, Denham JW, Shipley WU, Sandler HM, Feng FY, Joseph DJ, Armstrong JG, Dunne M, Malone S, Roy S, Zapatero A, Sun Y, Michalski JM, Spratt DE. Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S78-S79
    View PubMed
  31. Choo R, Hillman DW, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis B, Amundson A, Wong W. Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. Int J Part Ther. 2021 Fall; 8 (2):41-50 Epub 2021 Sept 14
    View PubMed
  32. Gao RW, Tollefson MK, Thompson RH, Potretzke AM, Quevedo FJ, Choo R, Davis BJ, Pisansky TM, Harmsen WS, Stish BJ. Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. Pract Radiat Oncol. 2021 Sep-Oct; 11 (5):e468-e476 Epub 2021 Feb 23
    View PubMed
  33. Breen WG, Stish BJ, Harmsen WS, Froemming AT, Mynderse LA, Choo CR, Davis BJ, Pisansky TM. The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. Radiother Oncol. 2021 Aug; 161:9-15 Epub 2021 May 21
    View PubMed
  34. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021 Aug; 80 (2):142-146 Epub 2021 May 10
    View PubMed
  35. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open. 2021 Jul 1; 4 (7):e2115312 Epub 2021 July 01
    View PubMed
  36. Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, Bazan J, Wong P, Yoon HA, Horton J, Gan G, Milano MT, Sigurdson ER, Moughan J, Salama JK, White J. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 1; 7 (6):845-852
    View PubMed
  37. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 1; 7 (4):544-552
    View PubMed
  38. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M 3rd, Sun Y, Lawton CAF. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2021 Jan 10; 39 (2):136-144 Epub 2020 Dec 04
    View PubMed
  39. Khairnar R, Pugh SL, Sandler HM, Lee WR, Villalonga Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng FY, Mishra MV. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS One. 2021; 16 (4):e0249123 Epub 2021 Apr 14
    View PubMed
  40. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 1; 109 (1):174-185 Epub 2020 Aug 27
    View PubMed
  41. Vargas CE, Thorpe CS, Dueck AC, Tenner KS, Davidson NE, Martino S, Pisansky TM, Hwang ES, Halyard MY, Pockaj BA, Perez EA. Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. Cancer. 2020 Dec 15; 126 (24):5239-5246 Epub 2020 Sept 15
    View PubMed
  42. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 Dec 1; 6 (12):1912-1920
    View PubMed
  43. Bai M, Gergelis KR, Sir M, Whitaker TJ, Routman DM, Stish BJ, Davis BJ, Pisansky TM, Choo R. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Med. 2020 Nov; 9 (21):7925-7934 Epub 2020 Sept 15
    View PubMed
  44. Gergelis KR, Kreofsky CR, Choo CS, Viehman J, Harmsen WS, Lester SC, Pisansky TM, Davis BJ, Stish BJ, Choo R. Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. Pract Radiat Oncol. 2020 Sep - Oct; 10 (5):e378-e387 Epub 2020 Feb 26
    View PubMed
  45. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 May 1; 6 (5):735-743
    View PubMed
  46. Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 Dec; 141:137-143 Epub 2019 Sept 17
    View PubMed
  47. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 Sep; 37 (9):599-610 Epub 2019 May 03
    View PubMed
  48. Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2019 Aug 1; 104 (5):1057-1065 Epub 2019 Apr 06
    View PubMed
  49. Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S. Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018. Pract Radiat Oncol. 2019 Jul - Aug; 9 (4):208-213 Epub 2019 Apr 30
    View PubMed
  50. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 Jul 1; 5 (7):975-983
    View PubMed
  51. Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiother Oncol. 2019 Jun; 135:19-24 Epub 2019 Mar 05
    View PubMed
  52. Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Pisansky TM, Chen Y, Sandler HM, Movsas B. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 1; 5 (5):664-670
    View PubMed
  53. Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019 Apr-Jun; 4 (2):314-322 Epub 2019 Feb 19
    View PubMed
  54. Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M 3rd, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019 Feb 1; 103 (2):335-343 Epub 2018 Oct 09
    View PubMed
  55. Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 Jan 20; 37 (3):213-221 Epub 2018 Dec 07
    View PubMed
  56. Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy. 2019 Jan - Feb; 18 (1):1-7 Epub 2018 Oct 04
    View PubMed
  57. Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018 Nov 10; 36 (32):3251-3258 Epub 2018 Sept 05
    View PubMed
  58. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov; 19 (11):1504-1515 Epub 2018 Oct 10
    View PubMed
  59. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 Jul; 74 (1):99-106 Epub 2017 Nov 09
    View PubMed
  60. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 May 10; 4 (5):e175230
    View PubMed
  61. Wilhite TJ, Routman D, Arnett AL, Glasgow AE, Habermann EB, Pisansky TM, Boorjian SA, Jethwa KR, Mynderse LA, Roberts KW, Frank I, Choo R, Davis BJ, Stish BJ. Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder (San Franc). 2018; 5 (3):e34 Epub 2018 Aug 23
    View PubMed
  62. Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Buskirk SJ. GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol. 2017 Jul; 90 (1075):20170174 Epub 2017 June 16
    View PubMed
  63. Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun 1; 98 (2):296-303 Epub 2017 Feb 12
    View PubMed
  64. Tendulkar RD, Agrawal S, Pisansky TM. Reply to T. Seisen et al and P. Ghadjar et al. J Clin Oncol 2017 May 1; 35 (13):1491-1492 Epub 2017 Jan 30
    View PubMed
  65. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 1; 97 (3):526-535 Epub 2016 Nov 17
    View PubMed
  66. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 Feb 02; 376(5):417-428.
    View PubMed
  67. Pisansky TM, Stish BJ. Reply to N. Fossati et al. J Clin Oncol 2017 Feb; 35 (4):470-471 Epub 2016 Nov 07
    View PubMed
  68. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 Dec 1; 96 (5):1046-1053 Epub 2016 Sept 03
    View PubMed
  69. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 Nov 10; 34 (32):3864-3871
    View PubMed
  70. Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6 (6):e291-e298 Epub 2016 May 20
    View PubMed
  71. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34 (30):3648-3654
    View PubMed
  72. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy Journal Of Clinical Oncology. 2016 Oct 20; 34: (30)3648-54.
  73. Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ. Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. BJU Int. 2016 Aug; 118 (2):236-42 Epub 2015 Aug 22
    View PubMed
  74. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 Jul 10; 34 (20):2325-32 Epub 2016 Apr 04
    View PubMed
  75. Mayo CS, Pisansky TM, Petersen IA, Yan ES, Davis BJ, Stafford SL, Garces YI, Miller RC, Martenson JA, Mutter RW, Choo R, Hallemeier CL, Laack NN, Ma DJ, Olivier KR, Keole SR, Fatyga M, Foote RL, Haddock MG. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Pract Radiat Oncol. 2016 Jul-Aug; 6 (4):e117-e126 Epub 2016 Jan 26
    View PubMed
  76. Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ. An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. PLoS One. 2016; 11 (3):e0151785 Epub 2016 Mar 17
    View PubMed
  77. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1; 33 (4):332-9 Epub 2014 Dec 22
    View PubMed
  78. Hallemeier CL, Davis BJ, Pisansky TM, Choo R. Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy. Urol Oncol. 2014 May; 32(4):496-500. Epub 2013 Dec 12.
    View PubMed
  79. Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, Bruner DW. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 2; 311 (13):1300-7
    View PubMed
  80. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32 (1):24.e1-6 Epub 2013 Mar 11
    View PubMed
  81. Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R. Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter. Am J Clin Oncol. 2013 Dec; 36(6):596-600.
    View PubMed
  82. Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2013 Nov; 31(8):1832-8. Epub 2012 Apr 25.
    View PubMed
  83. Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ. Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer. J Radiat Oncol. 2013 Sep 1; 2 (3):309-314
    View PubMed
  84. Peterson JL, Buskirk SJ, Heckman MG, Parker AS, Diehl NN, Tzou KS, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Pisansky TM. Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer. ISRN Oncol. 2013; 2013:239241 Epub 2013 Mar 31
    View PubMed
  85. Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer. Prostate. 2012 Dec 1; 72 (16):1757-66 Epub 2012 Apr 18
    View PubMed
  86. Hanisch LJ, Bryan CJ, James JL, Pisansky TM, Corbett TB, Parliament MB, Stewart CE, Hartford AC, Sandler H, Berk LB, Kachnic L, Bruner DW. Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer: analysis of RTOG 0215. Support Care Cancer. 2012 Nov; 20(11):2845-50. Epub 2012 Feb 22.
    View PubMed
  87. Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82 (5):1938-43 Epub 2011 Apr 20
    View PubMed
  88. Kovalchuk N, Furutani KM, Macdonald OK, Pisansky TM. Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Mar-Apr; 11(2):111-8.
    View PubMed
  89. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1; 29 (34):4491-7 Epub 2011 Oct 31
    View PubMed
  90. Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011 Sep 1; 81(1):1-7. Epub 2011 Apr 04.
    View PubMed
  91. Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med. 2011 Apr; 8(4):1228-38. Epub 2011 Jan 14.
    View PubMed
  92. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  93. Kachnic LA, Winter K, Wasserman T, Kelsen D, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Willett CG, Minsky BD. Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res. 2011 Mar; 4(2):45-52.
    View PubMed
  94. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 2010 Jul; 96(1):6-12. Epub 2010 Apr 17.
    View PubMed
  95. Bernard JR Jr, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK, Schild SE, Pisansky TM. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys. 2010 Mar 1; 76 (3):735-40 Epub 2009 May 21
    View PubMed
  96. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 1; 76(2):361-8. Epub 2009 Apr 23.
    View PubMed
  97. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Dec 01; 75(5):1364-70. Epub 2009 May 21.
    View PubMed
  98. Peterson JL, Buskirk SJ, Heckman MG, Crook JE, Ko SJ, Wehle MJ, Igel TC, Prussak KA, Pisansky TM. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol. 2009 Nov; 93 (2):203-6 Epub 2009 Sept 18
    View PubMed
  99. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1; 27 (16):2638-44 Epub 2009 Apr 06
    View PubMed
  100. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 1; 74(2):377-82. Epub 2008 Oct 22.
    View PubMed
  101. Halyard M, Pisansky T, Dueck A, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez E. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase I Trial N9831. J Clin Oncol. 2009; 27:2638-44.
  102. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc. 2008 Dec; 83 (12):1364-72
    View PubMed
  103. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Aug 1; 68(5):1417-23. Epub 2007 Apr 06.
    View PubMed
  104. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41.
    View PubMed
  105. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1; 67(2):327-33.
  106. Pisansky TM. Patterns of Care in Medicine Management of Prostate Cancer. 2007; 2(1):1-52.
  107. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys. 2007 Jan 1; 67(1):39-47.
    View PubMed
  108. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology. 2006 Dec; 68(6):1257-62. Epub 2006 Dec 04.
    View PubMed
  109. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006 Oct 12; 355(15):1583-91.
    View PubMed
  110. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int. 2006 Oct; 98(4):773-6.
    View PubMed
  111. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Oct 1; 107(7):1496-502.
    View PubMed
  112. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006 Sep; 176(3):985-90.
    View PubMed
  113. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Aug 1; 65(5):1487-93. Epub 2006 Jun 05.
    View PubMed
  114. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):975-81. Epub 2006 Jun 05.
    View PubMed
  115. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  116. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1140-50. Epub 2005 Sep 29.
    View PubMed
  117. Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy. 2006; 5(3):152-6.
  118. Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys. 2005 Nov 1; 63 (3):800-11
    View PubMed
  119. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2005 Nov 1; 63(3):795-9.
  120. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1673-84.
    View PubMed
  121. Wittmer MH, Pisansky TM, Kruse JJ, Herman MG. Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy. J Appl Clin Med Phys. 2005 Fall; 6 (4):1-13 Epub 2005 Nov 21
    View PubMed
  122. Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):956-64.
    View PubMed
  123. Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc. 2005 Jul; 80(7):883-98.
    View PubMed
  124. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol. 2005 Mar; 173(3):797-802.
    View PubMed
  125. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all? Int J Radiat Oncol Biol Phys. 2005 Feb 1; 61(2):409-14.
    View PubMed
  126. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005 Feb 1; 61(2):415-9.
    View PubMed
  127. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004 Nov 01; 60: (3)767-76.
    View PubMed
  128. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Hillman DW, Herman MG, King BF. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J. 2004 Nov-Dec; 10 (6):343-8
    View PubMed
  129. Eshleman JS, Davis BJ, Pisansky TM, Wilson TM, Haddock MG, King BF, Darby CH, Lajoie WN, Oberg AL. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004 Jun 1; 59 (2):419-25
    View PubMed
  130. Davis BJ, Brinkmann DH, Kruse JJ, Herman MG, LaJoie WN, Schwartz DJ, Pisansky TM, Kline RW. Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. Brachytherapy. 2004; 3: (2)106-12.
    View PubMed
  131. Pisansky TM. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:36-45
    View PubMed
  132. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):915-28.
    View PubMed
  133. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions' based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):929-43.
    View PubMed
  134. Herman MG, Pisansky TM, Kruse JJ, Prisciandaro JI, Davis BJ, King BF. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57 (4):1131-40
    View PubMed
  135. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 3; 349(1):17-26.
    View PubMed
  136. Davis BJ, Pisansky TM, Leibovich BC. Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Curr Opin Urol. 2003 Mar; 13 (2):117-22
    View PubMed
  137. Schwartz DJ, Davis BJ, Vetter RJ, Pisansky TM, Herman MG, Wilson TM, LaJoie WN, Oberg AL. Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy. 2003; 2(2):98-102.
    View PubMed
  138. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15; 20(20):4141-9.
    View PubMed
  139. Kruse JJ, Herman MG, Hagness CR, Davis BJ, Garces YI, Haddock MG, Olivier KR, Stafford SL, Pisansky TM. Electronic and film portal images: a comparison of landmark visibility and review accuracy. Int J Radiat Oncol Biol Phys. 2002 Oct 1; 54 (2):584-91
    View PubMed
  140. Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 1; 95(3):513-9.
    View PubMed
  141. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1; 20(5):1167-74.
    View PubMed
  142. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus. Results of the 1992-1994 Patterns of Care Study. Classic Papers and Current Comments. 2002; 6:742-50.
  143. Minsky B, Pajak T, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawara G, Rosenthal S, Kelsen D. Phase III Trial of Combined Modality Therapy for Esophageal Cancer: Standard Dose (50.4 Gy) vs. High Dose (64.8 Gy) Radiation Therapy J Clin Oncol. 2002.
  144. Schild SE, Pisansky TM. The role of radiotherapy after radical prostatectomy. Urol Clin North Am. 2001 Aug; 28 (3):629-37, x
    View PubMed
  145. Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT, Zincke H. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clin Proc. 2001 Jul; 76(7):702-6.
    View PubMed
  146. McCormick B, Strom E, Craighead PS, Kuske R, Hudis C, Ley J, Margolis L, Meyerwitz B, Morris E, Petrek J, Pierce L, Pisansky T, Rabinovitch R, Sneige N, Vicini F, Unger D, Winter K, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Breast Cancer Working Group. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):56-7.
    View PubMed
  147. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, Hammond E, Hanks G, Heydon KH, Kaufman DS, Lee WR, Michalski J, Mydlo J, Pisansky T, Pollack A, Porterfield H, Rifkin M, Roach M 3rd, Sanda M, True L, Vijayakumar S, Winter KA, Zeitman A, Radiation Therapy Oncology Group. Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):28-38.
    View PubMed
  148. Davis BJ, Pfeifer EA, Wilson TM, King BF, Eshleman JS, Pisansky TM. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol. 2000 Nov; 164 (5):1661
    View PubMed
  149. Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000 Nov 1; 56 (5):726-9
    View PubMed
  150. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman MG, Pisansky TM. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? Tech Urol. 2000 Jun; 6: (2)70-7.
    View PubMed
  151. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG. The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000 May; 6(5):1896-1899.
    View PubMed
  152. Pisansky TM, Davis BJ. Predictive factors in localized prostate cancer: implications for radiotherapy and clinical trial design. Semin Urol Oncol. 2000 May; 18(2):93-107.
    View PubMed
  153. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000 Apr; 163(4):1178-82.
    View PubMed
  154. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar; 163(3):845-50.
    View PubMed
  155. Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol. 2000 Feb; 13(2):113-8.
    View PubMed
  156. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000 Feb; 18(3):455-62.
    View PubMed
  157. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999 Oct; 5(10):2820-3.
    View PubMed
  158. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999 Jul; 162(1):98-102.
    View PubMed
  159. Cheng L, Cheville JC, Pisansky TM, Sebo TJ, Slezak J, Bergstralh EJ, Neumann RM, Singh R, Pacelli A, Zincke H, Bostwick DG. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol. 1999 Jul; 23(7):803-8.
    View PubMed
  160. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999 Jun 15; 85 (12):2630-7
    View PubMed
  161. Coia LR, Minsky BD, John MJ, Haller DG, Landry J, Pisansky TM, Willett CG, Hoffman JP, Berkey BA, Owen JB, Hanks GE. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. Cancer. 1999 Jun 15; 85(12):2499-505.
    View PubMed
  162. Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999 Mar 15; 85(6):1293-9.
    View PubMed
  163. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999 Feb 1; 43(3):517-23.
    View PubMed
  164. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, Iczkowski KA, Zincke H, Bostwick DG. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 1998 Nov 15; 83 (10):2164-71
    View PubMed
  165. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998 Jul; 16 (7):2377-81
    View PubMed
  166. Minsky BD, Coia L, Haller DG, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Berkey B, Katz A, Hanks G. Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. J Clin Oncol. 1998 Jul; 16(7):2542-7.
    View PubMed
  167. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998 May 1; 82(9):1784-8.
    View PubMed
  168. Minsky BD, Coia L, Haller D, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Hanks G. Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 1998 Apr 1; 41(1):21-7.
    View PubMed
  169. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998 Jan; 16(1):317-23.
    View PubMed
  170. Coia LR, Minsky BD, John MJ, Haller D, Landry J, Pisansky TM, Willet CG, Mahon I, Owen J, Hanks GE. Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. Radiat Med. 1998; 16:321-7.
    View PubMed
  171. Srigley JR, Hutter RVP, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors - renal cell carcinoma - workgroup no. 4. Cancer. 1997 Sep 1; 80(5):994-996.
    View PubMed
  172. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer. 1997 Jun 1; 79 (11):2154-61
    View PubMed
  173. Schomberg PJ, Shanahan TG, Ingle JN, Donohue JH, Kuske RR, Sternfeld WC, Wold L, Cha SS, Petersen IA, Brindle JS, Halyard MY, Bollinger JW, Hawkins R, Pisansky TM. Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study. Radiology. 1997 Feb; 202(2):565-9.
    View PubMed
  174. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 1997 Jan 15; 79 (2):337-44
    View PubMed
  175. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997 Jan; 49(1):65-70.
    View PubMed
  176. Schild SE, Pisansky TM, Kozelsky TF, Cha SS, Suman VJ, Burak SL, Ferrigni RG, Myers RP. Radiation therapy for elevated PSA levels after prostatectomy for prostate cancer. ASTRO School of Radiation Oncology: Prostate Cancer Symposium on Long Term Responses to Radiation, Atlanta, GA. 1997.
  177. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ, Grant CS, Hass AC, et al. Chemioterapia preoperatoria alternata nel trattamento del carcinoma mammario localmente avanzato: Risultati di uno studio pilota. Breast Cancer Digest. 1997:12-15.
  178. Coia LR, Minsky BD, John M, Pisansky TM, et al. 1996 decision trees and management guidelines. Semin Radiat Oncol. 1997; 7:163-81.
    View PubMed
  179. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Oct 1; 36 (3):585-91
    View PubMed
  180. Halyard MY, Grado GL, Schomberg PJ, Weaver AL, Grant CS, Pisansky TM. Conservative therapy of breast cancer. The Mayo Clinic experience. Am J Clin Oncol. 1996 Oct; 19 (5):445-50
    View PubMed
  181. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopezbeltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Workgroup 5 - assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996 Jul 15; 78(2):376-381.
    View PubMed
  182. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ Jr, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer. 1996 Jun 15; 77(12):2520-8.
    View PubMed
  183. Loprinzi CL, Okuno Sh, Okuno Sh, Pisansky TM, Sterioff S, Gaffey TA, Morton RF. Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Mayo Clin Proc. 1996 Jun; 71 (6):552-5
    View PubMed
  184. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Jan 1; 34 (1):33-9
    View PubMed
  185. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A 3rd. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol. 1996 Jan; 14(1):149-55.
    View PubMed
  186. Wold LE, Ingle JN, Pisansky TM, Johnson RE, Donohue JH. Prognostic factors for patients with carcinoma of the breast. Mayo Clin Proc. 1995 Jul; 70 (7):678-9
    View PubMed
  187. Minsky B, Neuberg D, Kelsen D, Pisansky TM, Ginsberg R, Benson III A. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus - a preliminary analysis of the phase II Intergroup trial 0122. Proc Am Soc Ther Radiol Oncol. 1995.
  188. Pisansky TM, Halyard MY, Weaver AL, Donohue JH, Grado GL, Grant CS, Hartmann LC, Ingle JN, Schomberg PJ, Wold LE. Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience. Mayo Clin Proc. 1994 Jun; 69 (6):515-24
    View PubMed
  189. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, Oesterling JE. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1993 Nov; 11: (11)2158-66.
    View PubMed
  190. Foo ML, McCullough EC, Foote RL, Pisansky TM, Shaw EG. Doses to radiation sensitive organs and structures located outside the radiotherapeutic target volume for four treatment situations. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27 (2):403-17
    View PubMed
  191. Pisansky TM, Ingle JN, Schaid DJ, Hass AC, Krook JE, Donohue JH, Witzig TE, Wold LE. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer. 1993 Aug 15; 72 (4):1247-60
    View PubMed
  192. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol. 1992 Oct; 15(5):376-87.
    View PubMed